First-Line Treatment of EGFR-Mutant NSCLC: TKI Alone or Combinations - What I Use Today and Why in the Latin America vs the World

被引：0

作者：

Bon, G. V. ^{[1
]}

de laia, E. A. ^{[1
]}

Peixoto, C. M. ^{[1
]}

Trotte, G. B. ^{[1
]}

de Oliveira, C. V. Y. ^{[1
]}

Silvestre, G. P. ^{[1
]}

da Costa, P. H. A. ^{[1
]}

Dias, R. T. ^{[1
]}

Martins, L. F. D. L. ^{[1
]}

Silva, C. D. C. E. ^{[1
]}

dos Santos, V. M. L. ^{[2
]}

机构：

[1] Univ Fed Fluminense, Niteroi, RJ, Brazil

[2] Inst Oncomed, Niteroi, RJ, Brazil

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

NSCLC; EGFR-TKI; Latin America;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP.12A.41

引用

页码：S638 / S638

页数：1

共 50 条

[1] Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy
Luo, F.
Liu, Y. Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S672
[2] Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
Sabari, J. K.
Yu, H. A.
Mahadevia, P.
Liu, Y.
Demirdjian, L.
Sultan, A. A.
Chen, Y. H.
Wang, X.
Passaro, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S620
[3] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
Tamura, Tomoki
Hotta, Katsuyuki
Gotoda, Hiroko
Kato, Yuka
Ichihara, Eiki
Kubo, Toshio
Tanimoto, Mltsune
Kiura, Katsuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
Xu, Q.
Liu, H.
Hang, T.
Ren, S.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
[5] EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Moore, Sara
Wheatley-Price, Paul
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1788 - 1792
[6] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Hafner, Susanne
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[7] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Susanne Hafner
Signal Transduction and Targeted Therapy, 6
[8] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
Robinson, N. D.
Zhan, P.
Udelsman, B.
Boffa, D. J.
Goldberg, S. B.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
[9] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Stock-Martineau, Sophie
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
[10] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
Xu, Qinghua
Liu, Hui
Meng, Shuyan
Jiang, Tao
Li, Xuefei
Liang, Shixiong
Ren, Shengxiang
Zhou, Caicun
JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529

← 1 2 3 4 5 →